Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 37956432.
- Also identified by DOI 10.7326/M23-2887 and PMC identifier 10644264.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In their article, Edelstein and colleagues provide the results of an observational study of virologic response in patients who received treatment with nirmatrelvir–ritonavir (N-R) versus those who received no COVID-19 therapy. The editorialists discuss the findings and emphasize the need for further consideration of the dosage, timing, and duration of treatment to inform optimal use of N-R.
Medical subject headings
- COVID-19